• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Intertek banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

MannKind announces deal with newly formed company

MannKind Corporation has announced an agreement to develop “multiple inhaled therapeutic products” with a company called Receptor Life Sciences, described as a “newly formed entity.” MannKind says that Receptor will license MannKind’s manufacturing technology and will be responsible for manufacturing and commercialization of the products as well as all development costs. MannKind says that the deal includes milestone payments of up to $102.25 million.

According to the announcement, “Receptor Life Sciences, Inc. is a pharmaceutical development company based in Seattle, Washington. Receptor is quietly laying the foundation for groundbreaking new products in the specialty pharmaceutical market.” A recently created web site for the company provides no information about its ownership or management, and a search for Receptor in the Washington Secretary of State corporations database returns no results as of January 21, 2016.

Newly appointed MannKind CEO Matthew Pfeffer said, “We are pleased that Receptor Life Sciences has selected our formulation and delivery technology to advance its portfolio of innovative inhaled products. This collaboration demonstrates the fundamental value of our platform technology while the risk-sharing structure of the transaction allows us to diversify our product opportunities without losing focus on our lead program.”

Pfeffer later responded to skepticism about Receptor LIfe Sciences with several tweets:

$MNKD CEO Matt Pfeffer, “Receptor Life Sciences is a completely independent entity from MannKind Corporation." #technosphere #MNKD2

— MannKind (@MannKindCorp) January 21, 2016

$MNKD CEO Matt Pfeffer, "Some partner companies want future product development plans kept under the radar, for competitive reasons." #MNKD2

— MannKind (@MannKindCorp) January 21, 2016

Read the MannKind press release.

Share

published on January 21, 2016

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Catalent banner
    © 2025 OINDPnews